



DOCKET NO.: BMS-2288/DM-6958A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Milind Rajopadhye, et al.

Confirmation No.: 3130

Application No.: 10/622,246

Group Art Unit: 1614

Filing Date: July 18, 2003

Examiner: Not Yet Assigned

For: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC  
DISORDERS

DATE OF DEPOSIT:

*April 7, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- ☒ In view of the voluminous nature of references 27, 58-61, 71, 76-77, 80, 87, 90, 92 and 96, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
  - ☒ Copies of references **1-53, 99-137, and 150-197** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/281,474**, filed **March 30, 1999** now **Publication No. 2002-0001566 A1** published **January 3, 2002**; copies of references **54-57 and 138-139** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/599,295**, filed **June 21, 2000** now **U.S. Patent No. 6,537,520**; copies of references **140-142** listed on the attached Form PTO-1449 were previously

DOCKET NO.: BMS-2288/DM-6958A - 4 -

PATENT


cited by or submitted to the Patent and Trademark Office in  
prior Application No. 10/342,081, filed **January 14, 2003**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-  
3050. This form is submitted in duplicate.

☐ The relevance of those listed references which are not in the English language is as  
follows:

☒ There are no listed references which are not in the English language.

Date: *April 7, 2004*

  
\_\_\_\_\_  
Brian J. Hubbard  
Registration No. 45,873

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2004 WW



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.	
	Filing Date July 18, 2003	Group 1614
	Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
1	Ashton, et al., <i>J. Org. Chem.</i> , <b>1996</b> , 61, 903-908	
2	Bakker, et al., <i>Life Sci.</i> , <b>1991</b> , 49, 1583-1591	
3	Barcelona, E.S., "Cilengitide/oncolytic angiogenesis inhibitor integrin alphavbeta3, alphabeta5 antagonist," <i>Drugs of the Future</i> , <b>2000</b> , 7(25), 674-678	
4	Batt, et al., <i>J. Med. Chem.</i> , <b>2000</b> , 43, 41-58	
5	Bevilacqua, et al., <i>Proc. Natl. Acad. Sci.</i> , <b>1987</b> , 84, 9238-9242	
6	Bousquet, et al., <i>Radiology</i> , <b>1988</b> , 166, 693	
7	Brechbiel, M., et al., <i>Bioconjugate Chem.</i> , <b>1991</b> , 2, 187	
8	Brechbiel, M., et al., <i>J. chem.. Soc. Perkin Trans.</i> , <b>1992</b> , 1, 1175	
9	Burke, P.A., et al., "Combined modality radioimmunotherapy/promise and peril," <i>Am. Can. Soc.</i> , February 15, <b>2002</b> , <i>Suppl. 4(94)</i> , 1320-1331	
10	Burris, et al., <i>Clin. Can. Res.</i> , <b>1995</b> , 1, 1623-1634	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
		Applicant Milind Rajopadhye, et al.	
		Filing Date July 18, 2003	Group 1614
		Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>11</b>	Burrows, et al., <i>J. of Controlled Release</i> , January <b>1994</b> , 28(1), 195-202	
	<b>12</b>	Burrows, et al., <i>Cancer Res.</i> , <b>1992</b> , 52, 5954-5962	
	<b>13</b>	Burrows, et al., <i>Proc. Nat. Acad. Sci. USA</i> , <b>1993</b> , 90, 8996-9000	
	<b>14</b>	Clauss, et al., <i>J. of Biological Chem.</i> , <b>1990</b> , 265(12), 7078-7083	
	<b>15</b>	DeGrado, et al., <i>J. Org. Chem.</i> , <b>1980</b> , 45, 1295-1300	
	<b>16</b>	Denekamp, J., et al., <i>Br. J. Cancer</i> , <b>1982</b> , 45, 136-139	
	<b>17</b>	Denekamp, J., et al., <i>Br. J. Cancer</i> , <b>1982</b> , 46, 711-720	
	<b>18</b>	Denekamp, J., <i>Acta Radiologica Oncology</i> , <b>1984</b> , 23 Fasc. 4, 217-225	
	<b>19</b>	Denekamp, J., <i>Cancer Meta. Rev.</i> , <b>1990</b> , 9, 267-282	
	<b>20</b>	DeNardo, et al., <i>Cancer Biotherapy &amp; Radiopharm.</i> , February <b>2000</b> , 15(1), 71-79	
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A		Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.		
	Filing Date July 18, 2003		Group 1614
	Confirmation No. 3130		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>21</b>	DiZio, et al., <i>Bioconjugate Chem.</i> , <b>1991</b> , 2, 353-366	
	<b>22</b>	Dvorak, et al., <i>Cancer Cells</i> , <b>1991</b> , 3, 77-85	
	<b>23</b>	Folkman, J., <i>Nature Medicine</i> , <b>1995</b> , 1, 27-31	
	<b>24</b>	Friedlander, et al., <i>Science</i> , <b>1995</b> , 270, 1500-1502	
	<b>25</b>	Ghose, et al., <i>Meth. Enzymology</i> , <b>1983</b> , 93, 280-333	
	<b>26</b>	Hagemeier, H.-H., et al., <i>Int. J. Cancer</i> , <b>1986</b> , 38, 481-488	
*	<b>27</b>	Haubner, V313 Nuclear-Medizin, March <b>1997</b>	
	<b>28</b>	Henry, T., et al., <i>J. Amer. College Cardiology</i> , <b>1998</b> , 31, 65A	
	<b>29</b>	Horton, et al., <i>Int. J. Biochem. Cell Biol.</i> , May <b>1997</b> , 29(5), 721-725	
	<b>30</b>	Hu, et al., <i>Oncology Res.</i> , <b>1994</b> , 6(7), 321-327	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A		Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.		
	Filing Date July 18, 2003		Group 1614
	Confirmation No. 3130		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>31</b>	Hubbrich, et al., <i>Liebigs Ann. Chem.</i> , <b>1979</b> , 776-783	
	<b>32</b>	Kennel, et al., <i>Nuclear Med. &amp; Biol.</i> , <b>1998</b> , 25, 241-246	
	<b>33</b>	Kerr, et al., <i>Anticancer Res.</i> , March/April <b>1999</b> , 19(2A), 958-958	
	<b>34</b>	Knowles, et al., <i>Analytical Biochemistry</i> , <b>1987</b> , 160, 440-443	
	<b>35</b>	Krenning, et al., <i>Digestion</i> , <b>1996</b> , 57, 57-61	
	<b>36</b>	Krenning, et al., <i>Eur. J. Nucl. Med.</i> , <b>1993</b> , 20, 716-731	
	<b>37</b>	Liu, S., et al., "90Y and 177Lu labeling of a dota-conjugated vitroneclin receptor antagonist useful for tumor therapy," <i>Bioconjugate Chemistry, Am. Chem. Soc.</i> , July <b>2001</b> , 4(12), 559-568	
	<b>38</b>	Liu, et al., <i>Inorg. Chem.</i> , <b>1999</b> , 38(6), 1326-1335	
	<b>39</b>	Manning, et al., <i>Tet. Lett.</i> , <b>1997</b> , 53, 11937-11952	
	<b>40</b>	Margerstadt, et al., <i>Magn. Reson. Med.</i> , <b>1986</b> , 3, 808	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A		Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.		
	Filing Date July 18, 2003		Group 1614
	Confirmation No. 3130		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>41</b>	Molema, et al., <i>Biochemical pharm.</i> , <b>1998</b> , 55, 1939-1945	
	<b>42</b>	Mueller, et al., <i>Proc. Natl. Acad Sci. USA</i> , <b>1992</b> , 89, 11832-11836	
	<b>43</b>	Nucl. Med., Proceeding of the 42 <sup>nd</sup> Annual Meeting, May <b>1995</b> , 36(5), No. 287, 71P	
	<b>44</b>	Olson, et al., <i>Int. J. Cancer</i> , <b>1997</b> , 73, 865-870	
	<b>45</b>	O'Reilly, et al., <i>Cell</i> , <b>1994</b> , 79, 315-328	
	<b>46</b>	Orlando, et al., <i>J. of Biological Chem.</i> , October <b>1991</b> , 266(29), 19543-19550	
	<b>47</b>	Runge, et al., <i>Radiology</i> , <b>1988</b> , 166, 835	
	<b>48</b>	Seillke, et al., <i>Drugs</i> , <b>1999</b> , 58(3), 391-396	
	<b>49</b>	Sipkins, et al., <i>Nature Medicine</i> , May <b>1998</b> , 4(5), 623-626	
	<b>50</b>	Takeshima, S., et al., <i>J. Clin. Invest.</i> , <b>1994</b> , 93, 662-670	
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A		Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.		
	Filing Date July 18, 2003		Group 1614
	Confirmation No. 3130		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>51</b>	Thorpe, et al., <i>Breast Cancer Res. &amp; Treat.</i> , <b>1995</b> , 36(2), 237-251	
	<b>52</b>	Van Waes, et al., <i>Intn'l J. of Oncology</i> , <b>2000</b> , 16, 1189-1195	
	<b>53</b>	Wellicome, et al., <i>J. Immunol.</i> , <b>1990</b> , 144(7), 2558-2565	
	<b>54</b>	Deshpande, S., et al., <i>J. Nucl. Med.</i> , <b>1990</b> , 31, 473	
	<b>55</b>	O'Reilly, et al., <i>Cell</i> , <b>1997</b> , 88, 277-285	
	<b>56</b>	Senger, et al., <i>Proc. Natl. Acad. Sci. USA</i> , <b>1997</b> , 94, 13612-13617	
	<b>57</b>	Srivatsa, et al., <i>Cardiovascular Res.</i> , <b>1997</b> , 36, 408-428	
*	<b>58</b>	Bodanszky, et al., <i>The Practice of Peptide Synthesis</i> , Springer-Verlag, New York, <b>1984</b>	
*	<b>59</b>	Bodanszky, <i>Peptide Chemistry: A Practical Textbook</i> , Springer-Verlag, New York, <b>1988</b>	
*	<b>60</b>	Brinkley, M., <i>Bioconjugate Chem.</i> , <b>1992</b> , 3(1)	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
		Applicant Milind Rajopadhye, et al.	
		Filing Date July 18, 2003	Group 1614
		Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	61	Bundgaard, H. (Ed.), Design of Prodrugs, <i>Elsevier</i> , 1985	
	62	Bundgaard, H., "Design and Applications of Prodrugs," Krogsgaard-Larsen, P., et al. (Eds.), <i>A Textbook of Drug Design and Development</i> , 1991, 113-191	
	63	Bundgard, H., "(C) Means to enhance penetration; (1) Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Delivery Reviews</i> , 1992, 8, 1-38	
	64	Burrows, F.J., et al., "Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy," <i>Clin. Can. Res.</i> , 1995, 1, 1623-1634	
	65	Chen, A.Y., et al., "DNA topoisomerase I-targeting drugs as radiation sensitizers," <i>Oncology</i> , October 1999, 13(10) Suppl. 5, 39-46	
	66	Cheung, S.T., et al., "N-methylamino acids in peptide synthesis. V. The synthesis of N-tert-butyloxycarbonyl,N-methylamino acids by N-methylation," <i>Can. J. Chem.</i> , 1977, 55, 906-910	
	67	Chou, T.-C., et al., "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors," <i>Adv. Enzyme Regul.</i> , 1984, 22, 27-55	
	68	Choy, H., "Taxanes in combined-modality therapy for solid tumors," <i>Oncology</i> , October 1999, 13(10) Suppl. 5, 23-38	
	69	Corbett, J.W., et al., "Solid-phase synthesis of a selective $\alpha_v\beta_3$ integrin antagonist library," <i>Biorg. Med. Chem. Lett.</i> , 1997, 7(11), 1371-1376	
	70	Cosic, I., et al., "In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide," <i>Mol. And Cell. Biochem.</i> , 1994, 130, 1-9	
EXAMINER		DATE CONSIDERED	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
		Applicant Milind Rajopadhye, et al.	
		Filing Date July 18, 2003	Group 1614
		Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	71	CRC Handbook of Chemistry and Physics, 65 <sup>th</sup> Ed., <i>CRC Press, Boca Raton, FL., 1984</i>	
	72	Dougher, A.M., et al., "identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor," <i>Growth Factors</i> , <b>1997</b> , <i>14</i> , 257-268	
	73	Friedlander, M., et al., "Definition of two angiogenic pathways by distinct $\alpha_v$ integrins," <i>Science</i> , <b>1995</b> , <i>270</i> , 1500-1502	
	74	Freidinger, R.M., et al., "Synthesis of 9-fluorenylmethyloxycarbonyl-protected <i>N</i> -alkyl amino acids by reduction of oxazolidinones," <i>J. Org. Chem.</i> , <b>1983</b> , <i>48</i> , 77-81	
	75	Gho, Y.S., et al., "Development of antiangiogenin peptide using a phage-displayed peptide library," <i>Cancer Res.</i> , September 1, <b>1997</b> , <i>57</i> , 3733-3740	
*	76	Greene, Protective Groups in Organic Synthesis, <i>John Wiley &amp; Sons, NY, 1981</i>	
*	77	Gross, et al., The Peptides: Analysis, Synthesis, Biology, <i>Academic Press, NY, 1980-1987, Vols. 1, 2, 3, 5 and 9</i>	
	78	Haubner, R., et al., "Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the $\alpha_v\beta_3$ integrin for a new cancer therapy," <i>Angew. Chem. Int. Ed. Engl.</i> , <b>1997</b> , <i>36</i> , 1374-1389	
	79	Herscher, L.L., et al., "Principles of chemoradiation: theoretical and practical considerations," <i>Oncology.</i> , October <b>1999</b> , <i>13(10) Suppl. 5</i> , 11-22	
*	80	Higuchi, T., et al., Pro-Drugs as Novel Delivery System, <i>Vol. 14</i> of the A.C.S. Symposium Series	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.	
	Filing Date July 18, 2003	Group 1614
	Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	<b>81</b>	Kakeya, N., et al., "Studies on prodrugs of cephalosporins. I. Synthesis and biological properties of glycyloxybenzoyloxymethyl and glycylaminobenzoyloxymethyl esters of 7 $\beta$ -[2-(2-aminothiazol-4-yl)-(Z)-2methoxyiminoscetamido]3-methyl-3-cephem-4-carboxylic acid," <i>Chem. Pharm. Bull.</i> , <b>1984</b> , 32, 692-698
	<b>82</b>	Merrifield, R.B., "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," <i>J. Am. Chem. Soc.</i> , <b>1963</b> , 85, 2149-2154
	<b>83</b>	Nielsen, N.M., et al., "Glycolamide esters as biolabile prodrugs of carboxylic acid agents: synthesis, stability, bioconversion, and physicochemical properties," <i>Journal of Pharmaceutical Sciences</i> , <b>1988</b> , 77(4), 285-298
	<b>84</b>	Notari, R.E., "[24] Theory and practice of prodrug kinetics," Widder, K.J. et al. (Eds.), <i>Methods in Enzymology, Drug anmd Enmzyme Targeting, Academic Press</i> , <b>1985</b> , 42, 309-396
	<b>85</b>	Ortéga, N., et al. "Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype," <i>Am. J. Pathol.</i> , November <b>1997</b> , 151(5), 1215-1224
	<b>86</b>	Ösapay, G., et al., "Synthesis of tyrocidine A: use of oxime resin for peptide chain assembly and cyclization," <i>Tetrahedron Letters</i> , <b>1990</b> , 31(43), 6121-6124
*	<b>87</b>	Protective Groups in Organic Synthesis, <i>John Wiley &amp; Sons, NY</i> , <b>1991</b>
	<b>88</b>	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., <i>Mack Publishing Co., Easton, PA</i> , <b>1985</b> , 1418
	<b>89</b>	Roberts, D.C., et al., "Unusual amino acids in peptide synthesis," <i>The Peptides</i> , <b>1983</b> , 5(6), 341-449
*	<b>90</b>	Roche, E.B. (Ed.), Bioreversible Carriers in Drug Design, <i>Am. Pharm. Assoc. &amp; Pergamon Press</i> , <b>1987</b>
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
		Applicant Milind Rajopadhye, et al.	
		Filing Date July 18, 2003	Group 1614
		Confirmation No. 3130	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	91	Rowinsky, E.K., "Novel radiation sensitizers targeting tissue hypoxia," <i>Oncology</i> , October 1999, 13(10) Suppl. 5, 61-70	
*	92	Schaper, W., et al., <i>Circulation: Heart, Brain, Kidney, Limbs, Kluwer Academic Publishers, Boston, 1993</i>	
	93	Soker, S., et al., "Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF <sub>165</sub> " <i>J. Biol. Chem.</i> , 1997, 272(50), 31582-31588	
	94	Stein, R., et al., "Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer," <i>Clin. Cancer Res.</i> , October 1999, 5, 3199s-3206s	
	95	Stewart, et al., <i>Solid Phase Peptide Synthesis</i> , 2 <sup>nd</sup> Ed., <i>Pierce Chem. Co., Rockford, IL, 1984</i> , page 88	
*	96	The Peptides: Analysis, Synthesis, Biology, <i>Academic Press, NY, 1981, Vol. 3</i>	
	97	Tran, T.-A., et al., "A novel RGD containing dodecapeptidomimetic which exhibits selective binding to the $\alpha_v\beta_3$ receptor," <i>Bioorg. &amp; Med. Chem. Lett.</i> , 1997, 7(8), 997-1002	
	98	Yayon, A., et al., "Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library," <i>Proc. Natl. Acad. Sci. USA</i> , November 1993, 90, 10643-10647	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>U. S. PATENT DOCUMENTS</b>							
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	
	99	4,248,802	02/03/81	Kuntz			
	100	4,472,509	09/18/84	Gansow, et al.			
	101	4,536,387	08/20/85	Sakamoto, et al.			
	102	4,859,777	08/22/89	Toner			
	103	4,988,827	01/29/91	Bergsteine, t al.			
	104	5,021,236	06/04/91	Gries, et al.			
	105	5,064,956	11/12/91	Kruper, et al.			
	106	5,087,440	02/11/92	Cacheris, et al.			
	107	5,155,215	10/13/92	Ranney			
	108	5,281,704	01/25/94	Love, et al.			
	109	5,342,757	08/30/94	Garin-Chesa, et al.			
	110	5,350,837	09/27/94	Bridger, et al.			
	111	5,376,356	12/27/94	Morgan, A.C., Jr.			
	112	5,382,654	01/17/95	Lyle, et al.			
	113	5,395,609	03/07/95	Stuttle, A.W.			
	114	5,403,713	04/04/95	Bevilacqua, et al.			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>U. S. PATENT DOCUMENTS</b>							
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	
	<b>115</b>	5,412,148	05/02/95	Keana			
	<b>116</b>	5,417,959	05/23/95	Wallace			
	<b>117</b>	5,520,904	05/28/96	Nosco, et al.			
	<b>118</b>	5,556,939	09/17/96	Flanagan, et al.			
	<b>119</b>	5,567,411	10/22/96	Keana, et al.			
	<b>120</b>	5,650,134	07/22/97	Albert, et al.			
	<b>121</b>	5,659,013	08/19/97	Senger, et al.			
	<b>122</b>	5,659,041	08/19/97	Pollak, et al.			
	<b>123</b>	5,660,827	08/26/97	Thorpe, et al.			
	<b>124</b>	5,679,810	10/21/97	Love, et al.			
	<b>125</b>	5,760,028	06/02/98	Jadhav, et al.			
	<b>126</b>	5,760,191	06/02/98	Snow, et al.			
	<b>127</b>	5,766,591	06/16/98	Brooks, et al.			
	<b>128</b>	5,776,427	07/07/98	Thorpe, et al.			
	<b>129</b>	5,780,426	07/1998	Palladino, et al.	514	9	
	<b>130</b>	5,801,228	09/01/98	Hollister, et al.			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>U. S. PATENT DOCUMENTS</b>							
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	
	131	5,804,161	09/08/98	Long, et al.			
	132	5,855,866	01/05/99	Thorpe, et al.			
	133	5,863,538	01/26/99	Thorpe, et al.			
	134	6,040,311	03/21/00	Duggan, et al.			
	135	6,051,207	04/18/00	Klaveness, et al.			
	136	6,056,973	05/02/00	Allen, et al.			
	137	6,143,274	11/07/00	Tweedle, et al.			
	138	5,801,228	09/01/98	Hollister, et al.			
	139	6,051,230	04/18/00	Thorpe, et al.			
	140	6,342,219	01/2002	Thorpe, et al.	424	145.1	
	141	2002/0147136	10/2002	Von Wronski, et al.	514	8	
	142	2002/0132774	09/2002	Klagsbrun, et al.	514	12	
	143	5,595,723	01/21/97	Quay	424	9.5	
	144	5,739,789	04/14/98	Kronhamn	342	465	
	145	5,744,120	04/28/98	Edwards	424	1.69	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2288/DM-6958A	Application No. 10/622,246
	Applicant Milind Rajopadhye, et al.	
	Filing Date July 18, 2003	Group 1614
	Confirmation No. 3130	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	146	5,750,088	05/12/98	Sworin, et al.	424	1.69
	147	5,767,071	06/16/98	Palladino, et al.	514	11
	148	5,770,565	06/23/98	Cheng, et al.	514	11
	149	60/013,360	03/13/96	Edwards		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	150	WO 81/01145	04/30/81	PCT			
	151	WO 90/93801	04/19/90	PCT			
	152	WO 90/05539	05/31/90	PCT			
	153	WO 90/12585	11/01/90	PCT			
	154	WO 90/13300	11/15/90	PCT			
	155	WO 91/01144	02/07/91	PCT			
	156	WO 91/14460	10/03/91	PCT			
	157	WO 91/15244	10/17/91	PCT			
	158	WO 92/12729	08/06/92	PCT			
	159	WO 92/17215	10/15/92	PCT			
	160	WO 92/19646	11/12/92	PCT			
	161	WO 93/08210	04/29/93	PCT			
	162	WO 93/17715	09/16/93	PCT			
	163	WO 93/23074	11/25/93	PCT			
	164	WO 94/05328	04/17/94	PCT			
	165	WO 94/11499	05/26/94	PCT			
	166	WO 94/22497	10/13/94	PCT			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	167	WO 95/25543	09/28/95	PCT			
	168	WO 96/00574	01/11/96	PCT			
	169	WO 96/01653	01/25/96	PCT			
	170	WO 96/31243	10/10/96	PCT			
	171	WO 96/41803	12/27/96	PCT			
	172	WO 97/08145	03/06/97	PCT			
	173	WO 97/16474	05/09/97	PCT			
	174	WO 97/18207	05/22/97	PCT			
	175	WO 97/23480	07/03/97	PCT			
	176	WO 98/14220	04/09/98	PCT			
	177	WO 98/16256	04/23/98	PCT			
	178	WO 98/47541	10/29/98	PCT			
	179	WO 99/06049	02/11/99	PCT			
	180	WO 99/13329	03/18/99	PCT			
	181	WO 99/40947	08/19/99	PCT			
	182	WO 99/58162	11/18/99	PCT			
	183	WO 02/04030	01/17/02	PCT			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2288/DM-6958A		Application No. 10/622,246	
				Applicant Milind Rajopadhye, et al.			
				Filing Date July 18, 2003		Group 1614	
				Confirmation No. 3130			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	184	0 107 734	07/29/87	EPO			
	185	0 606 683	07/20/94	EPO			
	186	0 359 347	03/21/90	EPO			
	187	0 436 005	10/07/91	EPO			
	188	0 727 225	08/21/96	EPO			
	189	5,314,694	07/21/94	AU			
	190	2 039 259	10/03/91	CA			
	191	2 232 315	04/10/97	CA			
	192	2 113 245	06/13/88	CA			
	193	2 156 620	10/14/94	CA			
	194	4 311 023	10/06/94	DE			
	195	19 536 781	03/27/97	DE			
	196	19 536 785	03/27/97	DE			
	197	19 725 368	12/17/98	DE			
	198	WO 94/22496	10/13/94	PCT			
	199	WO 94/22910	10/13/94	PCT			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			